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A B S T R A C T
Background
Pulmonary embolism (PE) can occur when a thrombus (blood clot) travels through the veins and lodges in the arteries of the lungs,
producing an obstruction. People who are thought to be at risk include those with cancer, people who have had a recent surgical
procedure or have experienced long periods of immobilisation and women who are pregnant. The clinical presentation can vary, but
unexplained respiratory symptoms such as difficulty breathing, chest pain and an increased respiratory rate are common.
D-dimers are fragments of protein released into the circulation when a blood clot breaks down as a result of normal body processes or
with use of prescribed fibrinolytic medication. The D-dimer test is a laboratory assay currently used to rule out the presence of high
D-dimer plasma levels and, by association, venous thromboembolism (VTE). D-dimer tests are rapid, simple and inexpensive and can
prevent the high costs associated with expensive diagnostic tests.
Objectives
To investigate the ability of the D-dimer test to rule out a diagnosis of acute PE in patients treated in hospital outpatient and accident
and emergency (A&E) settings who have had a pre-test probability (PTP) of PE determined according to a clinical prediction rule
(CPR), by estimating the accuracy of the test according to estimates of sensitivity and specificity. The review focuses on those patients
who are not already established on anticoagulation at the time of study recruitment.
Search methods
We searched 13 databases from conception until December 2013. We cross-checked the reference lists of relevant studies.
Selection criteria
Two review authors independently applied exclusion criteria to full papers and resolved disagreements by discussion.
We included cross-sectional studies of D-dimer in which ventilation/perfusion (V/Q) scintigraphy, computerised tomography pul-
monary angiography (CTPA), selective pulmonary angiography and magnetic resonance pulmonary angiography (MRPA) were used
as the reference standard.
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• Participants: Adults who were managed in hospital outpatient and A&E settings and were suspected of acute PE were eligible for
inclusion in the review if they had received a pre-test probability score based on a CPR.
• Index tests: quantitative, semi quantitative and qualitative D-dimer tests.
• Target condition: acute symptomatic PE.
• Reference standards:We included studies that used pulmonary angiography, V/Q scintigraphy, CTPA andMRPA as reference standard
tests.
Data collection and analysis
Two review authors independently extracted data and assessed quality using Quality Assessment of Diagnostic Accuracy Studies-2
(QUADAS-2). We resolved disagreements by discussion. Review authors extracted patient-level data when available to populate 2 × 2
contingency tables (true-positives (TPs), true-negatives (TNs), false-positives (FPs) and false-negatives (FNs)).
Main results
We included four studies in the review (n = 1585 patients). None of the studies were at high risk of bias in any of the QUADAS-2
domains, but some uncertainty surrounded the validity of studies in some domains for which the risk of bias was uncertain. D-dimer
assays demonstrated high sensitivity in all four studies, but with high levels of false-positive results, especially among those over the age
of 65 years. Estimates of sensitivity ranged from 80% to 100%, and estimates of specificity from 23% to 63%.
Authors’ conclusions
A negative D-dimer test is valuable in ruling out PE in patients who present to the A&E setting with a low PTP. Evidence from one
study suggests that this test may have less utility in older populations, but no empirical evidence was available to support an increase
in the diagnostic threshold of interpretation of D-dimer results for those over the age of 65 years.
P L A I N L A N G U A G E S U M M A R Y
D-dimer for excluding pulmonary embolism in hospital outpatient and accident and emergency populations
Review question
To investigate the ability of the D-dimer test to rule out a diagnosis of acute pulmonary embolism (PE) in patients treated in hospital
outpatient and accident and emergency (A&E) departments.
Background
Pulmonary embolism (PE) is a serious, potentially fatal condition that occurs when a blood clot becomes lodged in the blood vessels
of the lungs. When people arrive to hospital A&E departments reporting difficulty breathing, breathlessness and chest pain, several
explanations are possible but a quick diagnosis is needed. Tests that are available to detect blood clots in the lungs can be invasive and
time-consuming, can carry a radiation burden and may be costly. Quick, easy-to-use and inexpensive tests that can be used to rule out
the diagnosis would be very valuable.
One such test is the D-dimer test, which is so named because it detects small pieces of protein in the blood, which are called D-
dimer. When someone with symptoms of breathlessness and chest pain arrives to the hospital A&E department, the staff conducts an
examination and asks questions about the patient’s medical history and lifestyle. This helps them to calculate a score for the patient’s
risk that symptoms are due to a PE.
If the score shows that they are at high risk of a blood clot in the lungs, patients undergo diagnostic scanning immediately (or are
treated while test results are awaited). A D-dimer test can be ordered for people in low or moderate (or unlikely) risk groups; a negative
D-dimer result might rule out the diagnosis of PE without the need for imaging.
Study characteristics
This review considered all evidence provided by studies that assess the ability of D-dimer to rule out PE in people attending hospital
outpatient and A&E departments.
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We assessed all available reports from a wide search of databases of medical literature. Two review authors independently assessed studies
that met the review criteria, including use of a study design called a cross-sectional study; inclusion of people with symptoms of PE who
attended hospital outpatient and A&E departments; use of a risk score and then a D-dimer test; and comparison of results of the D-
dimer test against the results of the very best available tests - ventilation/perfusion scanning (V/Q scanning), pulmonary angiography,
computerised tomography pulmonary angiography, and magnetic resonance pulmonary angiography.
Key results
Four studies met our criteria, and data from 1585 patients were available. We found evidence that negative (disease absent) D-dimer
tests are very good at ruling out PE and identifying people without PE, but high numbers of false-positive test results suggest that
people with a raised D-dimer may not in fact have a PE; therefore, a positive result needs to be followed by imaging. In one study, false-
positives were more common among people older than 65 years of age.
Quality of the evidence
The flow of patients and the timing of D-dimer and reference standard tests were of greatest methodological concern; no study authors
provided a flow diagram to show the flow of patients throughout their study, and only one study clearly reported the time between
administration of index and reference standard tests. In the remaining three studies, timing between conduct of the index test and
completion of the reference standard was not clearly reported, leading to an unclear classification of bias.
Conclusions
Limited evidence from the studies included in this review suggests that quantitative D-dimer tests used in emergency departments have
few false-negatives but very high levels of false-positive results, with a high level of sensitivity consistently evident across all age groups.
This makes the test useful as a rule-out test but means that a positive result requires diagnostic imaging.
B A C K G R O U N D
Venous thromboembolism (VTE) is the collective term for deep
vein thrombosis (DVT) and pulmonary embolism (PE). PE can
occur when a thrombus (blood clot) travels through the veins and
lodges in the arteries of the lungs, producing an obstruction. A
variety of estimates have been presented for the incidence of PE in
different populations; in the USA, the number of first-time PEs
ranges from 71 to 117 cases per 100,000 (White 2003).
People thought to be at risk include those with cancer and those
who have had a recent surgical procedure, women who are preg-
nant and individuals who have experienced long periods of immo-
bilisation. The clinical presentation can vary, but unexplained res-
piratory symptoms such as difficulty breathing, chest pain and an
increased respiratory rate are commonly observed (Ainish 1999).
As these features can be present in a number of other condi-
tions, including myocardial infarction, pneumonia and heart fail-
ure (Goldhaber 1998), the diagnosis of PE can be difficult to rule
out on the basis of clinical presentation alone, and it is estimated
that only 25% of patients who present with symptoms and signs
of PE actually have the condition (van Belle 2006). Failure to
diagnose accurately and treat a PE can be fatal, and immediate
treatment with an anticoagulant to prevent development of fur-
ther clots is critically important (Andras 2012). Several radiologi-
cal and laboratory tests are used to diagnose PE; these tests exhibit
different accuracies, have different costs and, because some are in-
vasive and others non-invasive, are associated with different levels
of risk (Goodacre 2006; Yoo 2012).
D-dimers are fragments of protein released into the circulation
when a blood clot breaks down as a result of normal body processes
or with use of prescribed fibrinolytic medication. The normal level
of plasma D-dimer is usually less than 500 micrograms per litre
(µg/L) (upper limit of normal can vary depending on method of
measurement), and a higher level of D-dimer may be due to the
presence of a DVT or PE. D-dimers can be measured by an en-
zyme-linked immunosorbent assay (ELISA) or by use of coated
latex particles that agglutinate in the presence of plasma contain-
ing D-dimer, with the degree of agglutination directly proportion-
ate to the concentration of D-dimer in the plasma (Than 2009).
However, plasma D-dimer levels can be influenced by a person’s
age, by whether he or she has cancer or has had recent surgery
or by pregnancy, leading to false-positive test results. As D-dimer
antigen levels are raised in the acute phase of PE for around seven
days, patients with a PE who present late may have low levels of
D-dimer (Schreiber 2002).
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Use of D-dimer in the diagnostic pathway is usually preceded
by calculation of a pre-test probability with a clinical prediction
rule (CPR) such as the Charlotte or Wells score (see Figure 1 and
Clinical pathway section below). Patients who are judged likely to
have PE (have a high pre-test probability) do not usually receive
a D-dimer test; instead, they undergo computerised tomography
pulmonary angiography (CTPA) or ventilation/perfusion scintig-
raphy (V/Q scan). Patients judged to have a low pre-test prob-
ability are given a D-dimer test. If the result of the D-dimer is
positive, patients will then have a CTPA or V/Q scan. Those with
a negative D-dimer test result following a low probability CPR
score are considered to not have a PE (NCGC 2012).
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Figure 1. Clinical pathway.
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Aprevious systematic review included patients recruitedwithVTE
(that is, both DVT and PE) from both inpatient and outpatient
settings (Di Nisio 2007). Our Cochrane review will focus on pa-
tients with PE in the outpatient setting alone. Most inpatients
who experience symptoms or signs suggestive of PE are likely to
have a raised D-dimer for other reasons, making the test of little
use (Schrecengost 2003).
Tests used to reach a definitive diagnosis of PE include selective
pulmonary angiography,CTPA,V/Q scanning andmagnetic reso-
nance pulmonary angiography (MRPA). Selective pulmonary an-
giography is an invasive procedure involving insertion into the
vascular system, via the arm, groin or neck, of a catheter, which
is then guided until it reaches the pulmonary artery. Once the
catheter is in place, a contrast agent is injected into the catheter
and a series of x-rays are taken, allowing the contrast agent to indi-
cate blockages in the arteries. Aside from possible injury from the
catheter or contrast reaction, patients receive a dose of radiation.
During V/Q scanning, patients have to inhale a gaseous radionu-
clide and receive an injection of a radioactive agent. By detecting
radiation, a scintillation camera then captures images that show
circulation of both air and blood in the lungs. CTPA is less invasive
than pulmonary angiography but requires the use of a potentially
nephrotoxic contrast agent and x-rays. MRPA does not use x-rays
but instead models the response of hydrogen atoms within the
body to very strong magnetic fields to produce images. MRPA is
therefore unsuitable for patients fitted with pacemakers or other
metallic devices, and for those who suffer from claustrophobia,
owing to the fact that patients have to lie in a narrow space for
the MRPA scan to take place. Although it has been found to be
accurate for the diagnosis of proximal PE, MRPA exhibits limited
sensitivity for distal (small vessel) disease (Revel 2012) and requires
injection of a potentially nephrotoxic contrast agent. Both CTPA
and MRPA are considered less invasive and therefore are generally
used in preference to selective pulmonary angiography. V/Q scan-
ning is of limited value for those with other cardiorespiratory con-
ditions and is helpful in those with renal failure. However, all of
these tests have drawbacks, including their invasive nature, use of
chemicals, radiation burden and comparative lack of accessibility,
for example, computed tomography (CT) or magnetic resonance
(MR) scanner time is not always readily available for comparison
with the D-dimer test. Advantages of these tests over D-dimer in-
clude that they are more accurate and so can be used to diagnose
PE, while D-dimer can be used only to exclude PE. We will use
these tests as reference standards.
Target condition being diagnosed
Acute pulmonary embolism.
Index test(s)
The D-dimer test is a laboratory assay currently used to rule out
the presence of high D-dimer plasma levels and, by association,
PE. It is used as an add-on test in practice, and a normal D-dimer
on its own is sufficient to rule out PE in patients with a low or
moderate/unlikely score or unlikely pre-test probability from a
CPR. These tests use routine blood samples and are rapid, sim-
ple and inexpensive. D-dimer tests are classified in three different
ways according to the manner in which test results are obtained
(with final detection using fluorescence, immunosorbent assay or
agglutination techniques): quantitative, semi quantitative or qual-
itative (Goodacre 2006).
Quantitative D-dimer tests measure the plasma concentration of
D-dimer. Examples of these D-dimer tests include enzyme-linked
immunofluorescent immunoassays (ELFAs), microplate enzyme-
linked immunosorbent assays (ELISAs) and latex quantitative and
latex semi quantitative tests. Qualitative D-dimer tests are also
available. SomeD-dimer tests are available for point of care (POC)
use. They have a rapid turn-around time and are inexpensive. Lack
of standardisation of D-dimer assays means that results from one
assay cannot be generalised to other assays.
A systematic review by Becker 1996 found that a variety of thresh-
olds have been used in primary studies even for the same tests.
Therefore, we intend to include all evaluations of the diagnostic
test accuracy of D-dimer regardless of the threshold used to define
a positive test result.
Pre-test probability score using clinical prediction
rules (CPRs)
Assessment of the pre-test probability (PTP) of a PE is considered
a standard component of current clinical practice; therefore, we
included only studies that assess the PTP of PE using a CPR.
Many CPRs are available for assessing the PTP of PE; a systematic
review identified those that have been most extensively subjected
to validation (Ceriani 2010;Wells 1997).We included studies that
assess the PTP of PE using any of the following CPRs as part of the
diagnostic strategy involving any D-dimer test: Geneva (including
Revised and Revised Simplified), Wells (two-level, three-level and
simplified) and the Charlotte rule. Table 1 shows commonly used
CPRs and their scoring systems for assessment of the PTP of PE.
We did not use theMiniati rule, which was assessed in a systematic
review (Ceriani 2010), because it does not provide an easy method
of scoring patients: Users of the Miniati rule have to calculate a
probability from the co-efficients of a logistic regression model,
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As explained above, symptomatic patients generally undergo PTP
testing by the PE Wells test before they are given any D-dimer
test (Ceriani 2010; NCGC 2012; Wells 2006). The two-level
Wells test is a CPR that provides patient points for each criterion
met (e.g. previous history of PE or DVT, clinical signs of PE, re-
cent surgery or immobilisation, heart rate > 100 beats per minute
(bpm)). The maximum score is 12.5 points; the clinical probabil-
ity of PE is considered unlikely if the score is 4 or less, and high if
the score is higher than 4. The three-level Wells test uses the same
scoring system, with scores from 0 to 1 indicating low risk, 2 to 6
intermediate risk and higher than 6 high risk (Wells 2007).
Symptomatic patients considered to be at low risk by the CPR
will generally undergo D-dimer testing. A normal D-dimer in
patients with a low or unlikely PTP can be used to rule out PE.
In these circumstances, doctors will look for non-PE causes of the
symptoms. Patients with a low risk score but a positive D-dimer
test are referred for CTPA or V/Q scanning. Patients with a high
risk score usually do not receive a D-dimer test but are directly
referred for CTPA orV/Q scanning. Furthermore, patientsmay be
offered anticoagulation treatment before the CTPA scan if rapid
access is not available and they are classed as high risk by the CPR
or have a positive D-dimer test result.
Rationale
Pulmonary embolism is difficult to rule out on the basis of clinical
features. Although unnecessary treatment of patients with anti-
coagulants carries risk, the mortality rate for people with PE in
whom the condition is not recognised and consequently remains
untreated is 22% (Wells 2007). A quick, accurate diagnostic test
that can rule out the condition and reduce the need for diagnostic
imaging represents a clear improvement for treatment of people
with this acute condition.
O B J E C T I V E S
To investigate the ability of theD-dimer test to rule out a diagnosis
of acute PE in patients treated in hospital outpatient and accident
and emergency (A&E) settings who have had a pre-test probability
(PTP) of PE determined according to a clinical prediction rule
(CPR), by estimating the accuracy of the test according to estimates
of sensitivity and specificity. The review focuses on those patients
who are not already established on anticoagulation at the time of
study recruitment.
Secondary objectives
To investigate the following as potential sources of heterogeneity:
age, sex, previous PE, prolonged immobilisation and type of ref-
erence standard. We recognise that all of these listed items except
type of reference standard are patient-specific rather than study-
specific, and we anticipate that study reports may lack the neces-
sary level of detail to enable an informative analysis.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included cross-sectional studies evaluating the diagnostic test
accuracy of D-dimer and diagnostic cohort studies, including
both prospective and retrospective designs. We excluded diagnos-
tic case-control studies (two-gate design). Case-control designs are
known to overestimate the sensitivity and specificity of a diagnos-
tic test in clinical practice (Rutjes 2005). In this review, we consid-
ered studies that use a CPR with D-dimer testing to rule out PE in
patients treated in outpatient and A&E departments. Specifically,
we included studies that recruited symptomatic outpatients with
low-, intermediate- or high-risk CPR scores.
Participants
Adults treated in hospital outpatient and A&E settings and sus-
pected of acute PE as a result of clinical features such as breath-
lessness, chest pain, coughing up blood, increased respiratory rate,
tachycardia, low blood pressure and fainting, in whom a PTP of
PE has been assessed by a CPR for PE (examples of which can
be found above under the heading Index test(s)) were eligible for
inclusion in the review.When the data were available, we intended
to group patients according to whether or not they received anti-
coagulant treatment, the specific CPR and the D-dimer assay, as
these are not standardised (Schreiber 2002).
Patients with indeterminate or conflicting test resultsmay undergo
repeat imaging; the most commonly used imaging test for this
is CTPA or V/Q scanning, but eligibility criteria of the review
specify inclusion only of studies investigating the diagnostic ac-
curacy of the initial D-dimer test. We excluded studies that in-
cluded pregnant women, people with cancer and mixed groups of
patients, when results were not reported separately for those who
are pregnant or with and without cancer.
Index tests
Quantitative, semi quantitative and qualitative D-dimer tests.
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Target conditions
Acute pulmonary embolism (PE).
Reference standards
We included studies that used various reference standards (RS)
encompassing pulmonary angiography, V/Q scintigraphy, CTPA
and MRPA. We judged all patients’ D-dimer tests (index tests)
against these reference tests.
Search methods for identification of studies
Weapplied no restrictions in terms of date, language of publication
or publication status, and we used no diagnostic methodology
search filters.
Electronic searches
We searched the following databases (date of last search 12 De-
cember 2013).
• MEDLINE (Ovid SP).
• EMBASE (Ovid SP).
• Cumulative Index to Nursing and Allied Health Literature
(CINAHL) (via EBSCO).
• Latin American and Caribbean Health Science Information
Database (LILACS) (Bireme).
• Database of Abstracts of Reviews of Effects (DARE) and
the Health Technology Assessment Database (HTA) in The
Cochrane Library.
• Institute for Scientific Information (ISI) Conference
Proceedings Citation Index - Science.
• British Library Zetoc conference search (http://
zetoc.mimas.ac.uk/wzgw?f=f&form=conference&
id=31759069).
• MEDION (www.mediondatabase.nl/), via the ’Systematic
Reviews of Diagnostic Studies’ search filter.
We used the search strategies shown in Appendix 1; Appendix 2;
Appendix 3; Appendix 4; Appendix 5; Appendix 6; Appendix 7
and Appendix 8.
We searched the following trial databases for details of ongoing
and unpublished studies.
• World Health Organization International Clinical Trials
Registry Platform (http://apps.who.int/trialsearch/).
• ClinicalTrials.gov (http://clinicaltrials.gov/).
• Current Controlled Trials (http://www.controlled-
trials.com/).
We used the search strategies shown in Appendix 9; Appendix 10
and Appendix 11.
Searching other resources
We checked the reference lists of primary studies and reviews iden-
tified through electronic searches.
Data collection and analysis
Selection of studies
One review author (FC) screened titles and abstracts retrieved by
electronic searches, and a second review author (AA) checked a
random sample of 10% (n = 500) of identified titles and abstracts.
Disagreement was less than 80%, and we resolved disagreements
by discussion. One review author (FC) obtained and screened
782 full-text reports, identifying 54 full-text papers for potential
eligibility. Two review authors (FC andAA) independently applied
the inclusion criteria to all 54 full-text reports and disagreed about
the inclusion of five (9%) studies; after discussion, we excluded all
five studies. We present a PRISMA (Preferred Reporting Items for
Systematic Reviews and Meta-Analyses) flow diagram in Figure 2
to show the decision-making process for including studies in the
review (PRISMA 2009).
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Figure 2. Study flow diagram (see table of Excluded studies for reasons for full-text exclusions).
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Given that reporting in abstracts is necessarily sparse, we (FC and
AA) checked the full-text articles to ascertain the following: A 2
× 2 contingency table was supplied or could be back-calculated,
all patients were outpatients or A&E patients and had a PTP
calculated according to one of the specifiedCPRs and the reference
standard used was pulmonary angiography, CTPA, V/Q scanning
or MRPA. We reported in the PRISMA flow diagram the number
of studies failing these criteria.
Data extraction and management
Two review authors (FC and AA) independently replicated data
extraction using a standard form. Data collected included details
about study design, characteristics of the patient population (age,
sex, elements of patient history such as prolonged immobilisation,
cancer, recent surgical procedures or previous PE), D-dimer tests
given (nature of the D-dimer test such as ELISA, latex aggluti-
nation assay, whole blood agglutination), CPRs and all reference
standard tests used and data regarding the threshold applied for
each test. We also extracted the methods used to conduct each test
along with 2 × 2 accuracy data.
The 2 × 2 accuracy data comprise cross-tabulated results of D-
dimer tests and reference standards reported in 2 × 2 contingency
tables. We extracted patient-level data to populate 2 × 2 contin-
gency tables (true-positives (TPs), true-negatives (TNs), false-pos-
itives (FPs) and false-negatives (FNs)) as reported, or we back-
calculated data from estimates of sensitivity, specificity, positive
predictive value, negative predictive value and number of patients.
We extracted accuracy data and compared them for patient sub-
groups classified by PTP as low, intermediate and high.
The data extraction form incorporated a quality assessment section
comprising items fromQualityAssessment ofDiagnostic Accuracy
Studies-2 (QUADAS-2) (Whiting 2011). We collected data on
mortality, adverse events and numbers of technical failures for both
D-dimer and reference standard tests, when available, together
with information on the anticoagulant status of patients. Review
authors corroborated their extracted data and resolved differences
in quality assessment by discussion.
Assessment of methodological quality
We used the QUADAS-2 (Whiting 2011) to incorporate the re-
view question, a flow diagram when necessary and an assessment
of risk of bias and applicability judgements. Review-specific sig-
nalling questions and appropriate items concerning the applicabil-
ity of primary studies relative to the review, together with guidance
about ratings, can be found in Appendix 12. Two review authors
working independently piloted the data extraction and quality as-
sessment tools before use.
Statistical analysis and data synthesis
We extracted 2 × 2 contingency tables to estimate sensitivity and
specificity for each study. We intended that these estimates would
be used to create receiver operating characteristic (ROC) plots and
forest plots for all studies.
Quantitative D-dimer tests are used with explicit thresholds, and
500 µg/L is a common choice (Schouten 2013). If we had found
sufficient studies using this threshold, we would have performed
a bivariate random-effects model meta-analysis of sensitivity and
specificity to produce clinically applicable summary estimates of
sensitivity and specificity. However, we found only four studies in
total, and this method of meta-analysis was not possible with only
four studies. The bivariate (and equivalent hierarchical summary
receiver operating characteristic (HSROC)) model for meta-anal-
ysis of diagnostic studies requires estimation of five parameters.
It is a relatively complex meta-analysis model in comparison with
those used for randomised controlled trials (RCTs) owing to the
two-dimensional nature of the data (sensitivity and specificity).
Complex models need additional data to ensure adequate estima-
tion of all parameters.
We expected to include studies using qualitative D-dimer tests
with no explicit threshold, and sowewould have considered fitting
the HSROC model to the data and presenting results as summary
ROC (SROC) curves to give an indication of the global perfor-
mance of qualitative D-dimer tests (Harbord 2007), but again the
number of studies was insufficient for this analysis. In our proto-
col, we specified that we would need a minimum of six studies to
assess the suitability of studies for meta-analysis.
If themodel fit of the bivariate or HSROCmodel were not accept-
able, we considered performing univariate meta-analyses for sen-
sitivity and specificity. However, methodological differences be-
tween studies (e.g. type of D-dimer used) would have made the
results of any such meta-analysis dubious.
Investigations of heterogeneity
In our investigations of heterogeneity, we intended to specifically
investigate types of reference standards and age, sex and aspects
of patient history (prolonged immobilisation or previous PE) by
including these as co-variates in themeta-analysis (Di Nisio 2007).
We planned that each meta-regression would be carried out sep-
arately for each index test and each patient group by adding the
items as co-variates to the bivariate model. When data for our
prespecified variables were insufficient, we intended to consider
analysing one or two other items when data were available and
were considered to be clinically relevant, andwe intended to clearly
label these as post hoc in the review.
We intended thatwewould examine other potential sources graph-
ically for signs that they are a cause of heterogeneity (Smidt 2008).
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Wewould group estimates according to all items listed as potential
sources of heterogeneity and presented in forest and ROC plots
for visual assessment of heterogeneity.
However, we were unable to carry out any of our planned analyses
owing to an insufficient number of studies.
Sensitivity analyses
Weplanned toperform separatemeta-analyses on groups of studies
by which groups would be assigned according to CPR, anticoag-
ulant treatment and specific D-dimer assay. The disease spectrum
of patients could vary with CPR and thus affect the estimates of
sensitivity and specificity. We were aware that anticoagulant treat-
ment could cause disease progression bias if administered between
D-dimer testing and use of the reference standard. D-dimer assays
are not standardised and so may have different accuracies. Again,
given the small number of studies, we did not attempt to perform
any sensitivity analyses.
Assessment of reporting bias
Methods for dealing with publication bias in reviews of diagnostic
accuracy studies are relatively underdeveloped. Consequently, we
interpreted our results cautiously and with awareness of the like-
lihood of publication bias. Had we undertaken a meta-analysis of
data, wewould have considered using a funnel plot of the log of the
diagnostic odds ratio (lnDOR) (Deeks 2005) when heterogeneity
was low in the lnDOR.
R E S U L T S
Results of the search
See the study flow diagram (Figure 2).
We obtained and scrutinised a total of 54 full-text reports to assess
their eligibility for inclusion in the review. Forty-seven studies
(50 reports) did not meet the eligibility criteria, and we excluded
them (Barsotti 1987; Bounameaux 1988; Bounameaux 1991;
Bounameaux 1992; Christopher Study; Courtney 2008; deBastos
2008; Demers 1992; de Moerloose 1996; Djurabi 2009; Douma
2011; Eilas 2005; Faivre 1990; Friera-Reyes 2005; Gavaud 1996;
Geersing 2012; Ghanima 2005; Ghanima 2007; Goekoop 2007;
Harper 2007; Hirai 2007; Hochuli 2007; Hogg 2005; Kabrhel
2007; Kline 1997; Kline 2002; Kline 2006; Kovacs 2001; Laaban
1997; LeGal 2006; Legani 2009; Lucassen 2010; Lucassen 2013;
Parent 2007; Park 2008; Perrier 1996; Perrier 1997; Ray 2006;
Reber 2007; Righini 2004; Scarvelis 2008; Sebestyen 1990; Soo
Hoo 2011; Soons 2000; Than 2009; Waser 2005; Yamaki 2007).
We have provided details of the reasons for exclusion of each of
these studies in the Characteristics of excluded studies table. In
brief, a common reason for exclusion was the fact that studies
did not include all patients who had a D-dimer test in the anal-
ysis (e.g. all patients with a positive test result) (Courtney 2008;
deBastos 2008; Djurabi 2009; Friera-Reyes 2005; Ghanima 2005;
Ghanima 2007; Goekoop 2007; Kovacs 2001; Righini 2004). An-
other common reason for exclusion was the omission of a CPR in
the diagnostic pathway to assess the pre-test probability of study
patients (Bounameaux 1988; Bounameaux 1991; de Moerloose
1996; Demers 1992; Faivre 1990; Gavaud 1996; Harper 2007;
Kline 1997; Laaban 1997; LeGal 2006; Perrier 1996; Perrier 1997;
Ray 2006; Sebestyen 1990; Soons 2000). We were unable to ob-
tain copies of two reports (Ahamad 2000; Undurrage 2001) for
which citations are listed in the Studies awaiting classification sec-
tion. We have included four studies in the review (Gupta 2009;
Raviv 2012; Soderberg 2009; Sohne 2004).
Methodological quality of included studies
See Figure 3 and Figure 4.
Figure 3. Risk of bias and applicability concerns graph: review authors’ judgements about each domain
presented as percentages across included studies.
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Figure 4. Risk of bias and applicability concerns summary: review authors’ judgements about each domain
for each included study.
We have included four studies in the review (Gupta 2009; Raviv
2012; Soderberg 2009; Sohne 2004). The Characteristics of
included studies table incorporates the methodological quality as-
sessment. We assessed no study as having low risk of bias in all
domains, but we found no instances of high risk of bias in any of
the quality items. We explain below instances when we considered
study quality to be at unclear risk of bias. We grouped QUADAS-
2 quality assessment items into four domains: patient selection,
index test, reference standard and flow and timing.
In three studies (Gupta 2009; Raviv 2012; Sohne 2004), risk
of bias arising from patient selection was low, and in one study
(Soderberg 2009), the risk was considered to be unclear, because
although the variables used to calculate aWells score were prospec-
tively collected by investigators, the Wells pre-test probabilities
were scored retrospectively. All four studies recruited a consecu-
tive sample of patients with potential symptoms and signs of PE,
and all included patient populations appropriate for this review
question.
All four studies described the conduct of D-dimer index tests well,
but two studies reported no information about the thresholds used
to interpret D-dimer test results (Gupta 2009; Raviv 2012), lead-
ing to unclear risk of bias. All except one study provided a de-
scription of the reference standard (Raviv 2012), but three reports
did not provide information about the way reference standard test
results were interpreted (Gupta 2009; Raviv 2012; Sohne 2004).
Flow of patients and timing of the conduct of D-dimer and ref-
erence standard tests were of greatest methodological concern;
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no study authors provided a flow diagram to show the flow of
patients throughout their study, and only one study clearly re-
ported the time between conduct of index and reference standard
tests (Soderberg 2009). The remaining three studies (Gupta 2009;
Raviv 2012; Sohne 2004) did not clearly report the timing be-
tween conduct of the index test and use of the reference standard,
leading to an unclear classification of bias.
We have presented details of the conduct of D-dimer and reference
standard tests in the Characteristics of included studies table.
Findings
Four studies met the eligibility criteria, and we have included them
in the review (Gupta 2009; Raviv 2012; Soderberg 2009; Sohne
2004). Details of these studies can be found in the Characteristics
of included studies table. Below we summarise review findings,
including details of the patient population, CPRs used to calcu-
late pre-test probability, the index test, the diagnostic threshold
set by primary study authors and reference standards used to con-
firm the diagnosis. We have presented estimates of sensitivity and
specificity that we recalculated on the basis of accuracy data from
three studies (Gupta 2009; Soderberg 2009; Sohne 2004), and we
have reproduced reported estimates from the fourth study (Raviv
2012).
All D-dimer index tests evaluated were quantitative assays per-
formed on 1585 patients.
In the study by Gupta 2009, 627 patients with clinically sus-
pected PE presenting to the emergency department of a commu-
nity teaching hospital had their pre-test probability of PE scored
on the basis of the Geneva CPR (low clinical probability: 0 to 3
points; intermediate clinical probability: 4 to 10 points; high clin-
ical probability: 11 points or more). Investigators used Advanced
D-dimer™ Assay (Dade Behring, Inc, Deerfield, Illinois, USA)
with the diagnostic threshold set at, or above, 1.2 mg/L. They
confirmed the diagnosis by using computerised tomography pul-
monary angiography (CTPA) as the reference standard. For pa-
tients in the low clinical probability group, sensitivity was 100%
(95% confidence interval (CI) 61% to 100%) and specificity was
25% (95% CI 20% to 31%). For the intermediate clinical prob-
ability group, sensitivity was 100% (95% CI 82% to 100%) and
specificity 33% (95% CI 28% to 38%). Sensitivity and specificity
were 80% (95% CI 38% to 96%) and 37% (95% CI 15% to
65%) for the high clinical probability group, respectively.
Raviv 2012 recruited 300 people with a suspected presentation
of PE in the emergency room of a medical centre in Israel. The
index test used LIA test D-di (Stago-Diagnostica, Asnieres-sur-
Seine, France) thresholds between 800 ng/mL and 1000 ng/mL
(or equivalently, 800 mg/L and 1000 mg/L were used to evalu-
ate the accuracy of a higher D-dimer threshold) to rule out the
presence of PE. A modified Wells CPR classified patient pre-test
probability score as showing low or moderate risk. Most reference
standard tests were angiograms, but they could take the form of
other imaging tests, in particular, researchers used lung scans when
patients were unable to undergo CTPA. A D-dimer threshold of
900 mg/L was reported to achieve the highest sensitivity at 94.4%
and the highest specificity at 49.1%. Estimates of D-dimer accu-
racy in patients younger than 40 years of age were reported to be
higher (sensitivity 100% and specificity 54.9%). Unfortunately,
investigators provided no confidence intervals for these estimates,
and the differences may have arisen by chance. We were unable to
extract from the report the numbers of TPs, TNs, FPs, and FNs,
and failed to obtain this information from study authors.
Soderberg 2009 recruited 120 people attending the emergency
departments of two hospitals in Sweden who had a high clinical
probability of PE.. Investigators calculated pre-test probability us-
ing the Wells CPR, before using a rapid latex agglutination assay
(Tinaquant® , Roche, Basel, Switzerland) to measure D-dimer lev-
els tested on a whole plasma sample. The reference standard test
consisted of pulmonary angiography orCTPA, or both, performed
within 48 hours of the D-dimer test, and patients received low-
molecular-weight heparin at a dose of 175 to 200 U/kg subcuta-
neously, or unfractionated heparin 5000 IU intravenously, before
reference standard investigations were performed when results of
the D-dimer test were greater than the threshold of < 0.5 mg L−1.
Sensitivity was 91% (95% CI 81% to 97%) and specificity 63.0%
(95% CI 52% to 73%). The positive predictive value was 61%,
and the negative predictive value 92%.
Sohne 2004 recruited hospital inpatients and outpatients to a
study conducted at the AmsterdamMedical Centre in the Nether-
lands. General practitioners referred 538 outpatients for clinical
suspicion of acute PE. Investigators used the Wells CPR to calcu-
late pre-test probability scores and included in the study those at
low risk of PE. They used a rapid immunoturbidimetric D-dimer
assay (TinaquantD-dimer® , RocheDiagnostica,Mannheim,Ger-
many) to measure D-dimer levels. The threshold for a positive D-
dimer test result was 0.5 mg/L, and the reference standard was a
V/Q scan in combination with compression ultrasonography or
pulmonary angiography. Patients with abnormal reference stan-
dard test results were considered to have PE and received treat-
ment with anticoagulant therapy. Researchers followed up with all
patients at three months, and stratified estimates of sensitivity and
specificity for the outpatient population according to age. Among
people aged < 65 years, sensitivity was 100% (95% CI 97% to
100%) and specificity was 50% (95% CI 45% to 55%). For in-
dividuals between 65 and 75 years of age, sensitivity was 100%
(95% CI 85% to 100%) and specificity 31% (95% CI 20% to
44%). For people > 75 years of age, sensitivity was 100% (95%
CI 86% to 100%) and specificity 23% (95% CI 12% to 38%).
Estimates of D-dimer accuracy based on 2 × 2 data from the entire
study population were 100% (95% CI 97% to 100%) for sensi-
tivity and 45% (95% CI 40% to 50%) for specificity.
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Summary of findings
D-dimer test for excluding the diagnosis of pulmonary embolism
Population: people suspected of having a pulmonary embolism
Index test: D-dimer test
Target condition: pulmonary embolism
Reference standard: MRPA, pulmonary angiography, V/ Q scint igraphy and CTPA
Study design: cross-sect ional studies
Study ID D-dimer assay Threshold M ean age (SD or
range)
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CI: conf idence interval
CPR: clinical predicat ion rule
CTPA: computerised tomography pulmonary angiography
FN: false negat ives
FP: false posit ives
MRPA: magnetic resonance pulmonary angiography
PTP: pre-test probability
QUADAS-2: Quality Assessment of Diagnost ic Accuracy Studies-2
SD: standard deviat ion
TN: true negat ives
TP: true posit ives





































































































D I S C U S S I O N
Limited evidence provided by the studies included in this review
suggests that quantitative D-dimer tests used in emergency de-
partments result in few false-negatives but very high levels of false-
positive results, with a high level of sensitivity consistently evident
across all age groups. This makes the test useful as a rule-out test
but means that a positive result will require further investigation
with diagnostic imaging test(s).
All four studies reviewed reported high numbers of false-positives.
We found specificity to be lower among those over the age of
65 years in one study, and it appeared to decrease as patient age
increased, but this finding did not reach statistical significance
(Sohne 2004): D-dimer assays have been shown to possess low-
est specificity in those over 75 years of age, for whom the nat-
ural D-dimer concentration is expected to be higher (Schreiber
2002). The poor specificity of D-dimer has long been a concern
of those diagnosing pulmonary embolism (PE) who are keen to
find a cheap, quick and simple-to-use alternative to resource-in-
tensive diagnostic imaging tests and their potential adverse effects
(Kabrhel 2006).
Authors of another systematic review evaluating the performance
of D-dimer assays in older patients with suspected venous throm-
boembolism (VTE), which included some patients with PE
(Schouten 2013), reported age-related false-positive results. Data
from 13 cohorts of patients with VTE (n = 12,630), none of which
met the eligibility criteria for this review, showed an increase in
the number of false-positives with increasing age.
It has been suggested that one solution might be to use a higher
threshold for interpretation of D-dimer test results to improve
its specificity in older age groups. Unfortunately, we found no
evidence to support this suggestion; of the two studies with the
highest concentration thresholds of D-dimer, one did not present
accuracy data according to patient age (Gupta 2009), and we were
unable to extract accuracy data (true-positive (TP), true-negative
(TN), false-positive (FP) and false-negative (FN)) data from the
other study (Raviv 2012).
Only one study included patients with high pre-test probability
(PTP) scores (Gupta 2009); in this group, sensitivity was 80%,
compared with 100% in those with low or intermediate PTP. The
proportion of disease-positive patients (prevalence) varied among
different patient groups within studies and across studies. It has
been suggested that differences in the prevalence of disease among
populations can affect the accuracy of a test, but this does not ap-
pear to have influenced test accuracy in this circumstance (Leeflang
2009).
We were unable to perform a meta-analysis of 2 × 2 data because
of the small number of identified studies (n = 4), and we would
advise against over-interpretation of review findings.
Data from the studies included in our review show that dimer
assays can rule out PE, but the low specificity of positive testsmeans
that further research to try to refine the testing pathway is merited,
especially in older age groups. Healthcare professionals working in
emergency departments should be aware that using the D-dimer
test to rule out PE in older people may not lead to a reduction in
the ordering of other, more expensive tests. Therefore, the cost-
effectiveness of the diagnostic pathway deserves consideration by
those designing future research studies.
Summary of main results
We have tabulated a summary of the main results from this review
in Summary of findings.
Strengths and weaknesses of the review
The strength of this review is the adoption of high methodological
standards, in particular, screening of 4870 records and detailed
scrutiny of 54 studies allowed us to make important recommen-
dations for future research about the diagnostic accuracy of D-
dimer for excluding PE in outpatient and emergency patient pop-
ulations. These recommendations relate to both the methodologi-
cal conduct of future studies and the clinical question that remains
unanswered.
Weaknesses of the review include the small number of included
eligible studies, data from which were unsuitable for pooling in
a meta-analysis. Key differences between studies include differ-
ences between clinical prediction rules (CPRs), D-dimer assays
and thresholds used.
Applicability of findings to the review question
The findings of this review are applicable to the review question,
but in some included studies, information about interpretation of
index and reference standard test results is lacking, as are details
of the time period between administration of index and reference
standard tests. A high proportionof studies identified by our search
did not meet the eligibility criteria of the review, and we therefore
excluded them (Characteristics of excluded studies). In most cases,
we excluded studies because they did not include in the analysis all
patients who had a D-dimer test (e.g. all patients with a positive
test result), or they did not report reference standard test results for
all patients. These methodological weaknesses could result in bias
and over-estimation of the accuracy of the test. Another common
reason for exclusion was the omission of a CPR in the diagnostic
pathway used to assess study patients’ pre-test probability. As this is
standard clinical practice, we considered use of a CPR an essential
component of included studies, to ensure that findings of the
review were applicable to the review question and informative of
the usual diagnostic pathways found in routine clinical practice.
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A U T H O R S ’ C O N C L U S I O N S
Implications for practice
A negative D-dimer is useful in ruling out PE in patients who do
not have a high PTP of PE, but its clinical utility may diminish in
older people.
Implications for research
Well-designed studies are needed to evaluate whether the speci-
ficity of D-dimers can be improved without loss of sensitivity. The
diagnostic accuracy of interpretation of D-dimer test results using
higher thresholds in older patients is especially necessary, as has
been reported by others (Penaloza 2012). Future studies of the
diagnostic accuracy of D-dimer should contain analyses stratified
according to the different age groups of patients studied. Separate
analyses of patients based on their scores fromCPRs would also be
directly applicable to clinical decision making. Methodologically,
we suggest that all patients who receive a pre-test probability score
followed by a D-dimer test should have accuracy verified with a
reference standard test, and 2 × 2 data should be reported for the
whole study population. Future investigators should clearly report
details of the manner in which all test (index and reference stan-
dard) results are interpreted and the timing of administration of
index and reference standard tests.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Gupta 2009
Study characteristics
Patient sampling Cross-sectional study
Patient characteristics and set-
ting
627 patients; men n = 213 (34%); women n = 414 (66%). Mean age was 46.9 years (range 15 to
94). The study was conducted at a 500-bed community teaching hospital
Inclusion criteria: arrival to the emergency department with clinically suspected PE; acute onset
of new or worsening dyspnoea or chest pain without another obvious cause. D-dimer assay and
pulmonary CTA
Exclusion criteria Patients were excluded from the study if they had renal insufficiency, were pregnant
or chose not to undergo pulmonary CT
Patients had their pre-test probability calculated with the Geneva CPR as follows: low clinical
probability: 0 to 3 points; intermediate clinical probability: 4 to 10 points; high clinical probability:
11 or more points
Index tests The index test was a quantitative D-dimer assay (Advanced D-dimer™, Dade Behring, Inc, Deer-
field, Illinois, USA), an automated latex enhanced immunoturbidimetric assay. The assay was per-
formed with a Sysmex CA-1500 instrument (Sysmex America). 1.2 mg/L was the NVP cutoff for
VTE and PE. The threshold was 1.2 mg/L - the standard threshold at the study authors’ institution.
Patients received 100 mL/s of iopamidol (Isovue 370, Bracco) at a rate of 4 L/s IV. 50 millilitres of
normal saline solution was flushed IV after contrast administration
Target condition and reference
standard(s)
The target condition was clinically suspected PE. The reference standard was pulmonary comput-
erised tomography. Pulmonary CTA was performed with 16 MDCT scanner. All scans were ac-
quired at 1-mm section thickness. Imaging was performed approximately 15 to 20 seconds after
contrast IV. Determined with precise contrast tracking system (SureStart Toshiba Medical Systems)
. All readings of pulmonary CTA scans were rendered by a board-certified radiologist with 2 to 20
years’ experience




Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
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Gupta 2009 (Continued)
Was a case-control design
avoided?
Yes




DOMAIN 2: Index Test All tests




DOMAIN 3: Reference Standard
Is the reference standards likely




DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear






Patient sampling Retrospective cross-sectional study conducted between 01/01/2010 and 30/10/2010
Patient characteristics and set-
ting
300 patients; males n = 112 (37.34%), females n = 188 (62.66%). Mean age of females was 54.38
± 19.6 years and of males 53.7 ± 17.60 years
Inclusion criteria: patients with suspected clinical presentation of PE and with low or intermediate
pre-test clinical probability of PE calculated with a modified Wells CPR
Exclusion criteria: Patients with a high probability based on the Wells score were drawn out of the
study, as theywere not candidates for D-dimer testing according to the guidelines. Patients for whom
evaluation was incomplete or for whom any required data were insufficient were also excluded
Patients with suspected clinical presentation of PE were recruited from the emergency room of
BamBam Medical Centre, Northern Israel
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Raviv 2012 (Continued)
Index tests LIA test D-di (Stago Diagnostica, Asnieres-sur-Seine, France) thresholds between 800 ng/mL and
1000ng/mLwere used to determine themost appropriateD-dimer value that study authors regarded
as “standard”
Target condition and reference
standard(s)
The reference standard was reported as “imaging studies - default angiograms”
Flow and timing Timing between index and reference standard tests was not reported
Comparative
Notes Patients were stratified according to age as follows: 65 years and older, 40 to 65 years old, younger
than 40 years. A linear relationship was noted between patient age and D-dimer values, and a
statistically significant difference in D-dimer levels was observed between the older patient group
and each of the other groups
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes




DOMAIN 2: Index Test All tests




DOMAIN 3: Reference Standard
Is the reference standards likely




DOMAIN 4: Flow and Timing
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Raviv 2012 (Continued)
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear






Patient sampling Prospective cross-sectional study
Patient characteristics and set-
ting
120 patients; n = 43 men, n = 77 women. Mean age of people with PE was 57 years (range 27 to
80), mean age of people without PE 57 years (range 20 to 80). Clinical signs and symptoms of PE,
high clinical suspicion of PE, Wells pre-test probability score calculated from patient
medical notes retrospectively, with 4.0 or more points considered high risk. Data for scores of 3 and
6 were also analysed
Inclusion criteria: high clinical suspicion of PE and clinical signs and symptoms of PE, PA or CTPA
that could be performed within 48 hours
Exclusion criteria: (1) age younger than 18 years or older than 80 years, (2) advanced psychiatric
disease, (3) severe malnutrition or expected survival time less than 6 months, (4) signs of massive
unstable PE or 2 or more PEs or DVTs, (5) ongoing anticoagulant therapy, (6) thrombocytes < 70
× 109 L−1 or prolonged activated thromboplasmin time > 40 seconds, (7) known HIV or hepatitis
C infection, (8) pregnancy, (9) acute myocardial infarction, (10) serum creatinine > 150 µmol L−1,
(11) ongoing treatment with metformin, (12) contraindication to the use of contrast media
Patients with high clinical suspicion of PE were recruited from the emergency departments of 2
hospitals in Stockholm, Sweden
Index tests Rapid latex agglutination procedure (Tinaquant® , Roche), quantitative test, cutoff level < 0.5 mg/
L stated but not justified. D-dimer test was performed on a whole plasma sample
Target condition and reference
standard(s)
Acute PE was confirmed with computerised tomography pulmonary angiography (CTPA) or pul-
monary angiography (PA), or both, as the reference standard
Flow and timing The reference standard tests were conducted within 48 hours of D-dimer testing
Comparative
Notes Source of funding: Swedish Heart and Lung Foundation, Stockholm County Council, Karolinska
Institutet and Swedish Medical Council
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
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Soderberg 2009 (Continued)
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes




DOMAIN 2: Index Test All tests




DOMAIN 3: Reference Standard
Is the reference standards likely




DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes






Patient sampling Prospective cross-sectional study
Patient characteristics and set-
ting
538 patients (72% of 747); 72% of study participants (people at low risk of PE) were outpatients.
Mean age of people with PE was 62 years (range 14 to 95), those without PE had a mean age of 52
years (17 to 92)
Inclusion criteria: a consecutive sample of patients recruited from the Amsterdam Medical Centre
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Sohne 2004 (Continued)
(AMC) with clinical suspicion of PE, but non-high clinical probability
Exclusion criteria: younger than 18 years of age, pregnant, had received vitamin K antagonists or
heparin at a therapeutic dose for longer than 24 hours, had already undergone objective testing
for venous thromboembolism, had an indication for thromboembolism, written informed consent
could not be obtained
CPR used to calculate a pre-test probability was Wells, and a score ≤ 4 was regarded as a non-high
probability of PE
Index tests Plasma D-dimer concentration was measured by a quantitative rapid immunoturbidimetric D-
dimer assay (Tinaquant D-dimer®, Roche Diagnositica, Mannheim, Germany). The cutoff value
for a positive test result was 0.5 mg/L, which was stated but was not justified
Target condition and reference
standard(s)
The reference standard was V/Q scanning in combination with compression ultrasound or pul-
monary angiography
Flow and timing Timing between index and reference standard tests was not reported
Comparative
Notes Study authors reported 3-month follow-up of all patients to document the accuracy and safety of
the use of D-dimer in a low probability group
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes




DOMAIN 2: Index Test All tests




DOMAIN 3: Reference Standard
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Sohne 2004 (Continued)
Is the reference standards likely




DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear




CTPA: computerised tomography pulmonary angiography
CPR: clinical prediction rule
CT: computerised tomography
CTA: computerised tomography angiography
DVT: deep vein thrombosis
HIV: human immunodeficiency virus
IV: intravenous
MDCT: Multiple detector computerised tomography





Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Barsotti 1987 No 2 × 2 data; only 6/20 patients had pulmonary embolism
Bounameaux 1988 No CPR was used to assess patient pre-test probability
Bounameaux 1991 No CPR that met eligibility criteria was used to assess patient pre-test probability
Bounameaux 1992 Deep venous thrombosis, not PE
Christopher Study Not a diagnostic test accuracy study - a therapeutic impact study
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(Continued)
Courtney 2008 Patients with -ve D-dimer results did not receive reference standard imaging tests
de Moerloose 1996 No CPR was used to assess pre-test probability
deBastos 2008 Patients with -ve D-dimer results did not receive reference standard imaging tests
Demers 1992 No CPR was used to assess pre-test probability
Djurabi 2009 Patients with -ve D-dimer results did not receive reference standard imaging tests
Douma 2011 Not all members of population were treated in an outpatient setting, and data were not presented separately
Eilas 2005 No 2 × 2 data, reference standard unclear
Faivre 1990 No CPR was used to assess pre-test probability
Friera-Reyes 2005 Data on patients with +ve D-dimer were not included in the results
Gavaud 1996 No CPR was used to assess pre-test probability
Geersing 2012 Not all members of population were treated in an outpatient setting;data for those treated in an outpatient
setting were not presented separately
Ghanima 2005 Patients with -ve D-dimer results did not receive reference standard imaging tests
Ghanima 2007 Patients with -ve D-dimer results did not receive reference standard imaging tests
Goekoop 2007 Patients with -ve D-dimer results did not receive reference standard imaging tests
Harper 2007 Not all members of population were treated in an outpatient setting; CPR (e.g. Wells) not used, no reference
standards
Hirai 2007 DTA data for D-dimer not available - presented only for pulmonary angiography computerised tomography
(PACT)
Hochuli 2007 No 2 × 2 data
Hogg 2005 Reference standard tests included other D-dimer tests (IL D-dimer™ (Instrumentation Laboratory, Aragon,
Barcelona, Spain) and MDA D-dimer™ (Organon Teknika BV Boseind, Boxtel, The Netherlands))
Kabrhel 2007 Reference standardPET/CT, incomplete verification: only 183/541 (34%)patients received a reference standard
test
Kline 1997 No CPR was used to assess pre-test probability
Kline 2002 Not a diagnostic test accuracy study - a prognostic study
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(Continued)
Kline 2006 Incomplete verification; not all patients received a reference standard
Kovacs 2001 Patients with -ve D-dimer results did not receive reference standard imaging tests
Laaban 1997 No CPR was used to assess pre-test probability
LeGal 2006 CPR used does not meet review eligibility criteria
Legani 2009 Incomplete verification; not all patients received a reference standard
Lucassen 2010 Primary care outpatient population from Christopher study; not a diagnostic test accuracy study - a therapeutic
impact study
Lucassen 2013 This study is a summary and interpretation based on data published by the AMUSE study - Geersing 2012
Parent 2007 Not all members of population were treated in an outpatient setting; data for those treated in an outpatient
setting were not presented separately
Park 2008 Population included hospital inpatients. Contacted study authors for separate outpatient data - no response
Perrier 1996 No CPR was used to assess pre-test probability
Perrier 1997 CPR does not meet review eligibility criteria
Ray 2006 No CPR was used to assess pre-test probability
Reber 2007 Management study; lab-based study by the pharmaceutical industry - no reference standards
Righini 2004 Patients with -ve D-dimer results did not receive reference standard imaging tests
Scarvelis 2008 Patients with -ve D-dimer results did not receive reference standard imaging tests
Sebestyen 1990 Index test not a D-dimer (Fibrinopeptide A - FpA); no CPR
Soo Hoo 2011 Incomplete reference standard
Soons 2000 No CPR was used to assess pre-test probability
Than 2009 Nopre-test probability performed - some post-test probability performed, but numbers of patients who received
it not reported
Waser 2005 Deep venous thrombosis, not PE
Yamaki 2007 Deep venous thrombosis, not PE
CPR: clinical prediction rule
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CT: computed tomography
DTA: diagnostic test accuracy
PE: pulmonary embolism
PET: positron emission tomography
-ve: negative
+ve: positive
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Notes Unable to obtain report
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D A T A
This review has no data.
A D D I T I O N A L T A B L E S
Table 1. Examples of CPRs used for a pre-test probability score for PE
CPR Predictive elements and scoring system
Three-level Wells score Predictive elements of this CPR include clinical signs and symptoms of DVT (3 points), alter-
native diagnosis less likely than PE (3 points), heart rate > 100 beats per minute (1.5 points),
immobilisation for longer than 3 days or recent (< 4 weeks) surgery (1.5 points), previous VTE
(1.5 points), haemoptysis (1 point), cancer treatment in the previous 6 months or palliative care
(1 point)
Low probability - less than 2; intermediate probability - 2 to 6; high probability - more than 6
Two-level Wells score Predictive elements for the 2-level Wells score are the same as for the 3-level Wells score, but
patients are categorised into 2 as opposed to 3 categories, PE likely or PE unlikely based on a
score of more than 4 or 4 or fewer points, respectively
Simplified Wells score Same predictive elements are used as for the 3-level Wells score, but the point scoring has been
simplified - each item now scores 1 point. Patients are regarded as low risk if they have 1 point
or less, and as high risk if they score more than 1
Geneva score Predictive elements of the Geneva score include recent surgery (3 points), previous history of PE
or DVT (2 points), heart rate > 100 beats per minute (1 point), 60 to 79 years old (1 point),
80 years old or older (2 points), chest radiograph showing atelectasis (1 point), chest radiograph
showing elevated hemidiaphragm (1 point), partial pressure of oxygen (PaO2) < 49 mm Hg (4
points), PaO2 49 to 59 mmHg (3 points), PaO2 60 to 71 mmHg (2 points), PaO2 72 to 82 mm
Hg (1 point) and partial pressure of carbon dioxide (PaCO2) < 36 mm Hg (2 points), PaCO2
36 to 38.9 mm Hg (1 point)
Risk of PE is scored low (0 to 4 points), intermediate (5 to 8 points) or high (9 or more points)
Revised Geneva score Predictive elements of the revisedGeneva score include age >65 years (1 point), previous history of
PE or DVT (3 points), surgery with general anaesthesia or fracture within 1 month of symptoms
arising (2 points), active malignancy (2 points), heart rate 75 to 94 beats per minute (3 points),
heart rate > 94 beats per minute (5 points), pain on leg venous palpation and unilateral oedema
(4 points), haemoptysis (2 points) and unilateral leg pain (3 points)
This CPR is scored low risk (0 to 3 points), intermediate risk (4 to 10 points) or high risk (11
or more points)
Simplified revised Geneva score Same predictive elements are used as for the revised Geneva score, but point scoring has been
simplified. Each item now scores 1 point
Risk of PE is scored low (0 to 1 point), intermediate (2 to 4 points) or high (5 or more points)
Charlotte rule Elements of the Charlotte rule include > 50 years old, heart rate higher than systolic blood
pressure, unexplained hypoxaemia (O2 < 95%), recent surgery (previous 4 weeks), haemoptysis
and unilateral leg swelling
Risk score from the Charlotte rule is classified as safe (all predictive elements absent) or unsafe
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Table 1. Examples of CPRs used for a pre-test probability score for PE (Continued)
(any of the predictive elements present)
CPR: clinical prediction rule
DVT: deep vein thrombosis
PE: pulmonary embolism
VTE: Venous thromboembolism
A P P E N D I C E S
Appendix 1. MEDLINE search strategy
Database: Ovid MEDLINE(R) <1946 to November Week 3 2013>
Search Strategy:
--------------------------------------------------------------------------------
1 exp Pulmonary Embolism/ (31347)
2 (pulmonary adj embol$).ti,ab. (25289)
3 (pulmonary adj thrombo$).ti,ab. (3289)
4 (lung adj embol$).ti,ab. (377)
5 (lung adj thrombo$).ti,ab. (59)
6 (PE or PTE).ti,ab. (23195)
7 or/1-6 (59563)
8 Fibrin Fibrinogen Degradation Products/an, me [Analysis, Metabolism] (5667)
9 Biological Markers/an, bl, me [Analysis, Blood, Metabolism] (120309)
10 Enzyme-Linked Immunosorbent Assay/ (130387)
11 “Nephelometry and Turbidimetry”/ (6377)
12 d-dimer.ti,ab. (5726)
13 (fibrin adj2 d).ti,ab. (532)
14 dimeri?ed plasmin.ti,ab. (6)
15 elisa?.ti,ab. (112004)
16 elfa?.ti,ab. (120)
17 enzyme linked.ti,ab. (70920)
18 latex agglutination.ti,ab. (3168)
19 (latex adj3 assay?).ti,ab. (621)






26 “Instant I.A”.ti,ab. (7)
27 Vidas.ti,ab. (501)
28 LIATEST.ti,ab. (47)
29 (“IL test” or IL-DD).ti,ab. (29)
30 Turbiquant.ti,ab. (5)
31 Asserachrom.ti,ab. (52)
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32 Enzygnost.ti,ab. (200)
33 Fibrinostika.ti,ab. (6)
34 “BC DD”.ti,ab. (1)









44 (LPIA or EIA).ti,ab. (8470)
45 or/8-44 (343616)
46 7 and 45 (2690)
Appendix 2. EMBASE search strategy
Database: Embase <1980 to 2013 Week 49>
Search Strategy:
--------------------------------------------------------------------------------
1 lung embolism/ (58459)
2 (pulmonary adj embol$).ti,ab. (34552)
3 (pulmonary adj thrombo$).ti,ab. (4366)
4 (lung adj embol$).ti,ab. (598)
5 (lung adj thrombo$).ti,ab. (76)
6 (PE or PTE).ti,ab. (33967)
7 or/1-6 (92164)
8 fibrin degradation product/cr [Drug Concentration] (1)
9 biological marker/cr [Drug Concentration] (14)
10 D dimer/cr [Drug Concentration] (13)
11 enzyme linked immunosorbent assay/ (205450)
12 turbidimetry/ (2792)
13 d-dimer.ti,ab. (8597)
14 (fibrin adj2 d).ti,ab. (652)
15 dimeri?ed plasmin.ti,ab. (5)
16 elisa?.ti,ab. (155486)
17 elfa?.ti,ab. (186)
18 enzyme linked.ti,ab. (78011)
19 Immunoturbidimetr$.ti,ab. (1361)
20 turbidimetr$.ti,ab. (3317)
21 latex agglutination.ti,ab. (3477)
22 (latex adj3 assay?).ti,ab. (735)




27 “Instant I.A”.ti,ab. (8)
28 Vidas.ti,ab. (729)
29 LIATEST.ti,ab. (114)
30 (“IL test” or IL-DD).ti,ab. (88)
31 Turbiquant.ti,ab. (8)
32 Asserachrom.ti,ab. (130)
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33 Enzygnost.ti,ab. (252)
34 Fibrinostika.ti,ab. (7)
35 “BC DD”.ti,ab. (1)









45 (LPIA or EIA).ti,ab. (10588)
46 or/8-45 (284160)
47 7 and 46 (3250)
Appendix 3. CINAHL search strategy
Interface






S47 S7 AND S46 711
S46 S8 OR S9 OR S10 OR S11 OR S12 OR S13 OR S14 OR
S15 OR S16 OR S17 OR S18 OR S19 OR S20 OR S21 OR
S22 OR S23 OR S24 OR S25 OR S26 OR S27 OR S28 OR
S29 OR S30 OR S31 OR S32 OR S33 OR S34 OR S35 OR
S36 OR S37 OR S38 OR S39 OR S40 OR S41 OR S42 OR
S43 OR S44 OR S45
37,766
S45 TX LPIA or EIA 381
S44 TX Dimertest 2
S43 TX FDP 103
S42 TX stratus 50
S41 TX Innovance-DD 0
S40 TX HemosIL 6
S39 TX TintElize 0
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(Continued)
S38 TX biopool 4
S37 TX TriniLIZE 0
S36 TX Tinaquant or Tina-quant 14
S35 TX BC DD 2
S34 TX Fibrinostika 0
S33 TX Enzygnost 6
S32 TX Asserachrom 1
S31 TX Turbiquant 0
S30 TX IL test or IL-DD 82
S29 TX LIATEST 5
S28 TX Vidas 25
S27 TX Instant I.A 0
S26 TX NycoCard 8
S25 TX Minutex 0
S24 TX SimpliRed 18
S23 TX turbidimetr* 270
S22 TX Immunoturbidimetr* 71
S21 TX blood agglutination 239
S20 TX latex N3 assay? 6
S19 TX latex agglutination 107
S18 TX enzyme linked 12,863
S17 TX elfa? 10
S16 TX elisa? 249
S15 TX dimeri?ed plasmin 1
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(Continued)
S14 TX fibrin N2 d 60
S13 TX d-dimer 808
S12 (MH “Nephelometry and Turbidimetry”) 215
S11 (MH “Nephelometry and Turbidimetry”) 215
S10 (MH “Enzyme-Linked Immunosorbent Assay”) 10,786
S9 (MH “Fibrin Fibrinogen Degradation Products/AN/BL/
ME”)
540
S8 (MH “Biological Markers+/AN/BL/ME”) 24,146
S7 S1 OR S2 OR S3 OR S4 OR S5 OR S6 15,735
S6 TX PE or PTE 9,671
S5 TX lung N3 thrombo* 38
S4 TX lung N3 embol* 66
S3 TX pulmonary N3 thrombo* 1,347
S2 TX pulmonary N3 embol* 6,589
S1 (MH “Pulmonary Embolism”) 5,253
Appendix 4. LILACS search strategy
Database : LILACS 12 December 2013
Search on : (Fibrin Fibrinogen Degradation Products or Biological Markers or Enzyme-Linked Immunosorbent As-
say) [Subject descriptor] or (d-dimer or fibrin or (dimerised and plasmin) or elisa or elfa or (enzyme
and linked) or (latex and agglutination) or (latex and assay) or (blood and agglutination) or Immuno-
turbidimetr$ or turbidimetr$ or SimpliRed or Minutex or NycoCard or (Instant and I.A) or Vidas or
LIATEST or (IL and test) or IL-DD or Turbiquant or Asserachrom or Enzygnost or Fibrinostika or (BC
and DD) or Tinaquant or Tina-quant) [Words] and (Pulmonary Embolism [Subject descriptor]) or (
(pulmonary and embol$) or (pulmonary and thrombo$) or (lung and embol$) or (lung and thrombo$)
or PE or PTE) [Words]
References found : 62 [refine]
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Appendix 5. DARE (Database of Abstracts of Reviews of Effects) and Health Technology
Assessment Database (HTA) search strategy
Issue 11 2013
#1 MeSH descriptor: [Pulmonary Embolism] explode all trees 874
#2 pulmonary near/3 embol*:ti,ab,kw (Word variations have been
searched)
1679
#3 pulmonary near/3 thromb*:ti,ab,kw (Word variations have
been searched)
515
#4 lung near/3 embol*:ti,ab,kw (Word variations have been
searched)
165
#5 lung near/3 thromb* 64
#6 PE or PTE:ti,ab,kw (Word variations have been searched) 1320
#7 #1 or #2 or #3 or #4 or #5 or #6 2928
#8 MeSH descriptor: [Fibrin Fibrinogen Degradation Prod-
ucts] explode all trees and with qualifier(s): [Analysis - AN,
Metabolism - ME]
389
#9 MeSH descriptor: [Biological Markers] explode all trees and
with qualifier(s): [Analysis - AN, Blood - BL, Metabolism -
ME]
9822
#10 MeSH descriptor: [Enzyme-Linked Immunosorbent Assay]
explode all trees
1977
#11 MeSH descriptor: [Nephelometry and Turbidimetry] explode
all trees
64
#12 d-dimer or (fibrin near/2 d) or (dimeri* near/2 plasmin) or
elisa or elfa or “enzyme linked” or “latex agglutination” or
(latex near/j3 assay) or “blood agglutination” or Immunotur-
bidimetr* or turbidimetr* or SimpliRed or Minutex or Nyco-
Card or “Instant I.A” or Vidas or LIATEST or “IL test” or “IL-
DD” or Turbiquant or Asserachrom or Enzygnost or Fibrinos-
tika or “BC DD” or Tinaquant or “Tina-quant” or TriniLIZE
or biopool or TintElize or HemosIL or “Innovance-DD” or
stratus or FDP or Dimertest or LPIA or EIA:ti,ab,kw (Word
variations have been searched)
5391
#13 #8 or #9 or #10 or #11 or #12 14492
#14 #7 and #13 110
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Other Reviews (17) Trials (84) Methods Studies (0) Tech-
nology Assessments (1) Economic Evaluations (7) Cochrane
Groups (0)
Appendix 6. ISI Conference Proceedings Citation Index - Science search strategy
18 December 2013
Topic=(d-dimer) AND Topic=(pulmonary embolism or Thromboembolism or VTE)
Timespan=All years. Databases=CPCI-S, CCR-EXPANDED, IC
216
Appendix 7. British Library Zetoc search strategy
18 December 2013
16 for: conference: d-dimer and embolism
69 for: conference: d-dimer and thrombo*
Appendix 8. MEDION search strategy
19 December 2013
d-dimer: 9 results
Appendix 9. World Health Organization International Clinical Trials Registry search strategy
18 December 2013
21 records for 19 trials found for: d-dimer and embolism
Appendix 10. ClinicalTrials.gov search strategy
18 December 2013
65 studies found for: d-dimer and embolism
Appendix 11. Current Controlled Trials search strategy
18 December 2013
4 studies found for: d-dimer and embolism
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Appendix 12. QUADAS-2
Domains, signalling questions (SQ) and applicability Rating criteria
Domain 1: Patient selection
A. Risk of bias Describe the methods of patients’ selection given in the paper:
SQ1: Was a consecutive or random sample of patients enrolled? Yes: It is stated that the samplewas consecutive or a random sample
No: It is stated that the sample was not consecutive or a random
sample
Unclear: The method of sampling is ambiguous
SQ2: Did the study avoid inappropriate exclusions? Yes: The study excluded patients without CPR scores
No: The study excluded patients who had received a PTP score
using CPRs
Unclear:The test history of the patients in the study is not revealed
in the report
SQ3: Did the study avoid inappropriate inclusions? Yes: The study included only outpatients who had received a PTP
score for PE using a CPR
No:The study included some inappropriate patients, for example,
those without a PTP score from a CPR, or included inpatients
Unclear: The study’s inclusion criteria allow for inappropriate
inclusions
Applicability Question 1: Are there concerns that the included
patients and setting do not match the review question?
High: The study population meets the eligibility criteria
Low: The patient population is skewed in some way, for example
the study includes mainly younger patients
Unclear: Not enough information is given about the study pop-
ulation
B. Concerns regarding applicability Give the paper’s description of the inclusion/exclusion criteria,
including setting, prior tests, symptoms here
Domain 2: Index test
A. Risk of bias Give the paper’s description of the D-dimer assay, how it was
conducted and interpreted including the training of the individual
of those carrying out the test
SQ1: If a threshold was used was it prespecified? Yes: Plasma D-dimer levels are prespecified in the study methods
section as a positive test result
No: The threshold for a positive test result is not prespecified
Unclear: It is unclear if a threshold was used
B. Concerns regarding applicability
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(Continued)
AQ2: Are there concerns that the index test, its conduct or its
interpretation differ from the review question?
Yes: The plasma D-Dimer test did not use standard methods and
is unvalidated
No:The presence of plasma D-dimer was detected using standard
D-dimer test methods previously validated
Unclear: The basis of the outcome is unclear
Domain 3: Reference standard
A. Risk of bias Give the paper’s description of the pulmonary angiography,
scintigraphy, computed tomography PA and follow-up and how
they were conducted and interpreted including the training of the
individual of those carrying out the test
SQ1: Is the reference standard likely to correctly classify the target
condition?
Yes: The reference standard(s) was either pulmonary angiography,
CTPA, MRPA, or V/Q scanning
No: The reference standard(s) was not any of the above
Unclear: Information regarding the conduct of the reference stan-
dard is insufficient
SQ2: Were the reference standard test results interpreted without
knowledge of the index test results?
Yes: The person classifying the RS test results was unaware of the
D-dimer test results
No: The person classifying the RS test results was aware of the D-
dimer test results
Unclear: No information is available regarding the blinding of
test results
SQ3: Did the person conducting the pulmonary angiography, V/
Q scanning, CTPA, or MRPA have expertise comparable to a
radiologist?
Yes: It is stated that a radiologist or similar (e.g. vascular specialist
with an interest in VTE) read the test results
No: The person conducting the pulmonary angiography, V/Q
scanning, CTPA, or MRPA was not a radiologist or similar
Unclear: The expertise and background discipline of the reader is
not made clear
Applicability: Could the reference standard, its conduct, or its
interpretation have introduced bias?
High: The RS tests were performed by a person with expertise
and were interpreted blind
Low: The RS tests were not performed by a person with expertise
or were not interpreted blind
Unclear:No information about the persons conducting the tests,
or interpreting the results is given
Domain 4: Flow and timing
A. Risk of bias Describe the reasons why any patient recruited into the study did
not contribute to the 2 x 2 table (i.e. patients who did not undergo
the RS tests) referring to the flow diagram
SQ1: was there an appropriate interval between the index test and
the reference standard?
Yes: The index and reference standard tests were all conducted
within 7 days of each other
No: Some of the reference standard test results were obtained after
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(Continued)
more than 7 days
Unclear: No information about the relative timing of the tests is
provided
SQ2: Did all the patients receive the same reference standard? Yes: A complete set of RS test results are available for all study
patients
No: The RS results are not available for all patients, or some
patients had follow-up only
Unclear: It is not clear whether all patients received an acceptable
reference standard
SQ3: Were all patients included in the final analysis? Yes: Data for all study patients are reported
No: Data for all study patients are not reported
Unclear: It is not clear whether there were patients recruited but
not included in the 2 x 2 table
WH A T ’ S N E W
Date Event Description
23 September 2016 Amended Correction of minor error and omission in plain language summary identified by German trans-
lation team
C O N T R I B U T I O N S O F A U T H O R S
The whole review team has contributed to this review. KWdeveloped the search strategy. FC and AA applied eligibility criteria, extracted
data from studies, performed an assessment of study quality and entered data into Review Manager. FMC provided expert statistical
and KS and DK expert clinical advice.
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to attend ISTH and EAHAD meetings.
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FMC: none known.
This review forms part of work funded by a National Institute of Health Research (NIHR) Cochrane programme grant. The review
was conducted independently of our funders, the NIHR. The NIHR had no input on the conduct or results of the review.
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
We have added accident and emergency (A&E) room to the study setting to reflect conventional reporting that we encountered in
studies considered for inclusion in this review. We were unable to carry out a search of the Cochrane DTA Register.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Acute Disease; Biomarkers [blood]; Cross-Sectional Studies; False Negative Reactions; False Positive Reactions; Fibrin Fibrinogen
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